Wellness company Medifast (NYSE: MED) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 34.3% year on year to $76.04 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $70 million was less impressive, coming in 6.3% below expectations. Its GAAP loss of $0.19 per share was 63.5% above analysts’ consensus estimates.

Is now the time to buy Medifast? Find out by accessing our full research report, it’s free.

"We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been leading indicators of future growth. Backed by our differentiated science, coach-led model, and a disciplined approach to managing costs, we believe we are well positioned to drive improved performance through the remainder of 2026 and a return to sustainable, long-term growth in the years ahead,” said Dan Chard, CEO of Medifast.

Company Overview

Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE: MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years.

With $346.1 million in revenue over the past 12 months, Medifast is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.

As you can see below, Medifast struggled to generate demand over the last three years. Its sales dropped by 39.1% annually, a poor baseline for our analysis.

This quarter, Medifast’s revenue fell by 34.3% year on year to $76.04 million but beat Wall Street’s estimates by 9.9%. Company management is currently guiding for a 33.7% year-on-year decline in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to decline by 24.3% over the next 12 months. it’s hard to get excited about a company that is struggling with demand.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Cash Is King

Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.

Medifast has shown weak cash profitability relative to peers over the last two years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 1.6%, below what we’d expect for a consumer staples business.

Key Takeaways from Medifast’s Q1 Results

We were impressed by Medifast’s optimistic EPS guidance for next quarter, which blew past analysts’ expectations. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its revenue guidance for next quarter missed and its gross margin fell slightly short of Wall Street’s estimates. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 3% to $10.95 immediately following the results.

Sure, Medifast had a solid quarter, but if we look at the bigger picture, is this stock a buy? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).